[1] Algoet M, Janssens S, Himmelreich U, et al.Myocardial ischemia-reperfusion injury and the influence of inflammation[J]. Trends Cardiovasc Med, 2023, 33(6):357-366.
[2] Caruso I, Giorgino F.SGLT-2 inhibitors as cardio-renal protective agents[J]. Metabolism, 2022,12(7):154937.
[3] 李小龙,李田昌,王琦.SGLT2抑制剂心血管获益新进展[J].中国循证心血管医学杂志, 2020, 12(6):763-764,768.
[4] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J].中华心血管病杂志, 2019, 47(10):766-783.
[5] Park Y, Jin S K, Lee J H, et al.Effect of Ticagrelor on Left Ventricular Remodeling in Patients With ST-Segment Elevation Myocardial Infarction (HEALING-AMI)[J]. JACC. Cardiovascular Interventions, 2020, 13(19):2220-2234.
[6] 潘斯斯,梁贵友.细胞焦亡在心肌缺血再灌注损伤中的研究进展[J].中华医学杂志, 2021, 101(21):1627-1630.
[7] Algoet M, Janssens S, Himmelreich U, et al.Myocardial ischemia-reperfusion injury and the influence of inflammation[J]. Trends Cardiovasc Med, 2023,33(6):357-366.
[8] Baker HE, Tune JD, Mather KJ, et al.Acute SGLT-2i treatment improves cardiac efficiency during myocardial ischemia independent of Na+/H+°exchanger-1[J]. Int J Cardiol, 2022,36(9):138-148.
[9] Seefeldt JM, Lassen TR, Hjortbak MV, et al.Cardioprotective effects of empagliflozin after ischemia and reperfusion in rats[J]. Sci Rep, 2021,11(1):9544.
[10] Nikolaou PE, Efentakis P, Abu Qourah F, et al.Chronic Empagliflozin Treatment Reduces Myocardial Infarct Size in Nondiabetic Mice Through STAT-3-Mediated Protection on Microvascular Endothelial Cells and Reduction of Oxidative Stress[J]. Antioxid Redox Signal, 2021,34(7):551-571.
[11] 赵莉,李智.达格列净干预对急性心肌梗死合并2型糖尿病患者经皮冠状动脉介入术后心室重构,心肌微灌注的影响[J].陕西医学杂志, 2022, 51(1):81-84.
[12] 王伟,刘星雨,尚云龙,等.基于血清药物化学与网络药理学探究麝香通心滴丸治疗冠心病的机制[J].中成药,2020,42(10):2768-2777.
[13] 姚玉斯,曾智桓,赵艳群,等.麝香通心滴丸改善猪心肌缺血再灌注后冠脉微循环和心功能[J].南方医科大学学报,2020,40(6):899-906.
[14] 吴刚,余德龙,李磊,等.麝香通心滴丸对缺血性心力衰竭心肌纤维化和血管再生的影响机制[J].中国实验方剂学杂志,2021,27(1):141-146.
[15] 黎人榕, 佘强. SGLT2抑制剂在动物模型中治疗心肌缺血再灌注损伤的机制[J]. 临床医学进展, 2023, 13(2): 2232-2240.
[16] 郑云涛,邓兵,郑望,等.麝香通心滴丸对急性心肌梗死经皮冠状动脉介入治疗患者炎性因子及心功能的有益作用[J].国际心血管病杂志, 2021, 48(2):116-119. |
